Cellectar Biosciences, Inc. (CLRB)
3.15
+0.01
(+0.32%)
USD |
NASDAQ |
May 19, 14:35
Cellectar Biosciences Research and Development Expense (Quarterly) : 3.007M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Karyopharm Therapeutics, Inc. | 33.78M |
| Ocugen, Inc. | 11.26M |
| Invivyd, Inc. | 30.73M |
| ACADIA Pharmaceuticals, Inc. | 76.87M |
| Alnylam Pharmaceuticals, Inc. | 364.87M |